Table 4.

Characteristics of patients withCEBPA DM that have remission material available

Patient ID	RNA frequency at diagnosis, %*	Skewing†	RNA frequency at remission, %*	GATA2 mutations‡		GATA2 allele expressed§	CEBPA mutations||	CEBPA mutation VAF
				n	Type (VAF)			Diagnosis		Remission
								Mut1	Mut2	Mut1	Mut2
13975	41.21	Not skewed	44.48	0	—	—	N/C	0.396	0.459	0.000	0.000
14006	17.81	Skewed	47.66	0	—	—	N/N	0.882	HMZ	0.000	HMZ
14347	16.96	Skewed	46.79	1	ZF1 (0.49)	Mut (0.82)	N/C	0.457	0.420	0.000	0.183
17658	25.65	Skewed	49.15	0	—	—	N/N	0.457	0.460	0.001	0.000
18522	23.43	Skewed	46.39	0	—	—	C/C	0.781	HMZ	0.001	HMZ
24783	37.22	Skewed	47.73	0	—	—	N/C	0.446	0.436	0.000	0.000
24819	28.66	Skewed	42.23	1	ZF1 (0.06)	Mut (0.10)	N/C	0.401	0.316	0.000	0.000
27899	24.73	Skewed	42.33	0	—	—	N/C	0.470	0.460	0.000	0.000
27977	0.01	Monoallelic	0.56	0	—	—	N/C	0.503	0.434	0.000	0.501
36832	41.03	Not skewed	40.58	0	—	—	N/C	0.438	0.389	0.000	0.000
40126	12.85	Skewed	47.57	2	ZF1 (0.12), ZF1 (0.07)	Mut (0.16), mut (0.11)	N/C	0.469	0.469	0.000	0.000
47293	14.71	Skewed	41.46	0	—	—	N/C	0.435	0.459	0.000	0.001

HMZ, homozygous; mut, mutated allele.

^*Indicates the proportion of reads from the minor allele for each single-nucleotide polymorphism considered, determined at diagnosis or remission.

^†Categorized as monoallelic for RNA frequency ≤0.10 or skewed for RNA frequency ≤0.35.

^‡Reports the VAF of the mutation at the DNA level.

^§Includes the VAF measured in the RNA.

^||VAF of the 2 CEBPA mutations is indicated in N- to C-terminal order, at diagnosis and remission.